Deciphering the therapeutic efficacy of FGF19 and FGF21 in NAFLD: A comparative genomic and metabolic analysis
-
Published:2024-08
Issue:
Volume:60
Page:104394
-
ISSN:2212-4292
-
Container-title:Food Bioscience
-
language:en
-
Short-container-title:Food Bioscience
Author:
Wei Lengyun,
Long Pengpeng,
Ye Xianlong,
Zhu ShenglongORCID,
Cui Siyuan
Reference45 articles.
1. The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis;Abdelmalek;Contemporary Clinical Trials,2021
2. Subcutaneous delivery of FGF21 mRNA therapy reverses obesity, insulin resistance, and hepatic steatosis in diet-induced obese mice;Bartesaghi;Molecular Therapy - Nucleic Acids,2022
3. Pegbelfermin (BMS-986036), PEGylated FGF21, in patients with obesity and type 2 diabetes: Results from a randomized phase 2 study;Charles;Obesity,2019
4. FGF19 analog as a surgical factor mimetic that contributes to metabolic effects beyond glucose homeostasis;DePaoli;Diabetes,2019
5. Why we need to curb the emerging worldwide epidemic of nonalcoholic fatty liver disease;Diehl;Nature Metabolism,2019